AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Natera, Inc.
Video analysis: NTRA
All videosNo video analysis for this stock yet. Request one from our team.
News: NTRA
Arizona State Retirement System Purchases 2,899 Shares of Natera, Inc. $NTRA
Arizona State Retirement System grew its position in Natera, Inc. (NASDAQ: NTRA) by 8.1% in the undefined quarter, according to its most recent filing with the SEC. The firm owned 38,604 shares of the medical research company's stock after buying an additional 2,899 shares during the period. Arizona State Retirement System's holdings in
Billionaire Stanley Druckenmiller Has 2 Megacap Stocks Worth Watching (Hint: His Top Holding Isn't Amazon, Alphabet, or Nvidia)
Stanley Druckemiller holds some smaller positions in Amazon and Alphabet. His largest stockholding is a company called Natera, which does DNA diagnostics.
Why Moderna's Cancer Vaccine Matters to Investors
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.
New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in patients with both newly diagnosed and relapsed/refractory (R/R) lymphoma. PET/CT scans serve as the standard tool for assessing treatment response in lymphoma, but their performance is limited, with positive predictive value (PPV) reported as low as 50%.
Caisse de depot et placement du Quebec Buys New Shares in Natera, Inc. $NTRA
Caisse de depot et placement du Quebec bought a new position in Natera, Inc. (NASDAQ: NTRA) in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 2,517 shares of the medical research company's stock, valued at approximately $683,000. A number of other institutional
Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run?
The billionaire has good reasons to like this genetic testing leader.
Natera & Angiex Partner to Evaluate AGX101 Response With Signatera
NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.
Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a national partnership with Susan G. Komen®, the world's leading breast cancer organization. Together, the organizations aim to accelerate breast cancer awareness and education, including efforts to increase understanding of MRD. Natera's SignateraTM MRD test is supported by more than 185 peer-reviewed publications across multiple cancer types, including.
Similar companies
-
Mettler-Toledo International Inc.
MTD
·
New York Stock Exchange
Compare
-
Waters Corporation
WAT
·
New York Stock Exchange
Compare
-
BioNTech SE
BNTX
·
NASDAQ
Compare
-
Quest Diagnostics Incorporated
DGX
·
New York Stock Exchange
Compare
-
Teva Pharmaceutical Industries Limited
TEVA
·
New York Stock Exchange
Compare
-
Koninklijke Philips N.V.
PHG
·
New York Stock Exchange
Compare